TD Asset Management Inc Boosts Position in Boston Scientific Corporation $BSX

TD Asset Management Inc boosted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 0.9% during the second quarter, Holdings Channel reports. The firm owned 2,180,194 shares of the medical equipment provider’s stock after buying an additional 19,270 shares during the quarter. TD Asset Management Inc’s holdings in Boston Scientific were worth $234,175,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of BSX. Sound Income Strategies LLC raised its holdings in shares of Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 120 shares during the last quarter. 1248 Management LLC acquired a new position in shares of Boston Scientific in the first quarter worth $26,000. Y.D. More Investments Ltd acquired a new position in shares of Boston Scientific in the first quarter worth $27,000. Oliver Lagore Vanvalin Investment Group acquired a new position in shares of Boston Scientific in the second quarter worth $37,000. Finally, Activest Wealth Management raised its holdings in shares of Boston Scientific by 6,216.7% in the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock worth $38,000 after acquiring an additional 373 shares during the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $94.92 on Tuesday. The firm has a market capitalization of $140.64 billion, a PE ratio of 56.50, a P/E/G ratio of 2.30 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The business has a 50-day moving average of $101.75 and a two-hundred day moving average of $101.84. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm’s revenue was up 22.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Transactions at Boston Scientific

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the sale, the director owned 2,081 shares in the company, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 174,214 shares of company stock valued at $17,972,457. Insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

BSX has been the subject of a number of analyst reports. Wells Fargo & Company boosted their price target on Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a report on Thursday, July 24th. Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $118.00 to $125.00 in a report on Monday, September 8th. BTIG Research upped their target price on Boston Scientific from $127.00 to $132.00 and gave the company a “buy” rating in a research note on Wednesday, October 1st. Leerink Partners upped their target price on Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $125.00 target price on shares of Boston Scientific in a research note on Monday, September 29th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Boston Scientific currently has a consensus rating of “Buy” and an average price target of $120.71.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.